Navigation Links
EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
Date:10/24/2007

re, in a Phase 1 clinical study conducted by the National Cancer Institute with Panzem(R) Capsules, an ovarian cancer patient with the clear cell subtype experienced a durable partial response to 2ME2 lasting over three years after failing three prior chemotherapy regimens.

Carolyn F. Sidor, M.D., EntreMed Vice President and Chief Medical Officer commented on the study, "Results from this study continue to demonstrate that Panzem(R) NCD has modest activity and an excellent safety profile as a single agent in heavily pretreated and refractory ovarian cancer patients. The stage is now set for us to consider additional trials where Panzem(R) NCD can be combined with approved agents in an attempt to provide clinical benefit to patients with advanced cancers."

To view the poster presentation, visit the Company's web site at http://www.entremed.com.

About Ovarian Cancer

Ovarian cancer accounts for 4% of all cancers among women in the United States, and ranks fifth as the cause of cancer deaths. The American Cancer Society estimates that there will be approximately 22,000 newly diagnosed cases of ovarian cancer in the U.S. in 2007 resulting in approximately 15,000 deaths. About half of all ovarian cancers occur in post-menopausal women. Ovarian cancer is frequently asymptomatic in the early stages. As a result, ovarian cancer is often not diagnosed until stage III or IV, where 5-year survival rates decline to 10-20%. Current drug therapy involves paclitaxel and carboplatin/cisplatin regimens. Many patients develop resistance to these drugs, so there is substantial need for innovative therapies that can overcome resistance, either as a single agent or in combination with cytotoxic agents.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2M
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Experimental treatment for Ebola Virus Shows promising results in mice
8. Hormone Deficiency Results In Miscarriage
9. Gleevec gets hopeful results
10. Breast Implants May Interfere With The Interpretation Of Mammogram Results
11. DNA Testing For More Accurate Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 2015 Thousands of aesthetic industry professionals ... sponsored by the American Society for Aesthetic Plastic Surgery ... was Zeltiq, the parent company of one of the ... With blazing growth, the one-of-a-kind device just sold its ... is currently in the news for gaining the FDA’s ...
(Date:5/30/2015)... York (PRWEB) May 30, 2015 ... $100 million in punitive and compensatory damages to ... who suffered serious complications following implantation of the ... a verdict rendered on May 28th in Delaware ... in compensatory damages after the jury found that ...
(Date:5/30/2015)... ROTHWELL, Australia (PRWEB) May 30, 2015 At ... the rewards of vibrant health , which she attributes ... personally tested principles of good nutrition with the release of ... ” (published by Xlibris AU). , “Cook for Health and ... using natural, nutritious and mostly organic food . It ...
(Date:5/30/2015)... San Francisco, CA (PRWEB) May 30, 2015 ... San Francisco, California, is proud to announce their June ... a featured apartment community in San Francisco, Key Housing ... find quality housing in what is one of the ... Francisco is a plum posting, and understandably anyone who ...
(Date:5/30/2015)... Nevada (PRWEB) May 30, 2015 Venus ... of acne scars, large pores, deep wrinkles, stretch marks, ... licensed medical professional, such as Dr. F. Victor Rueckl ... of the clinical trials in Las Vegas. This body ... technology into a system that delivers proven results through ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 2Health News:San Francisco Corporate Housing Leader Key Housing Designates 388 Beale Street as Featured Community for June 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... affordable protease inhibitor for patients in developing countries ... MYL ) today announced that Matrix Laboratories ... a 71.5% controlling interest, received the first and ... Tablets, 200 mg/50 mg. Matrix,s version of this ...
... healthcare professionals demonstrating exceptional service, sacrifice and innovation ... ANGELES, Feb. 25 Beginning March 1, 2009, ... Inspired Comfort Awards program. Since 2003, the ... awarded more than 70 outstanding healthcare professionals for ...
... the Leader in Technology-Enabled Telehealth Solutions, Adds Accomplished Financial Executive to ... ... 25, 2009 -- American TeleCare, Inc. (ATI) announced that Michael A. ... is the leader in the development and application of video-based telehealth ...
... (NYSE Alternext US: FIT), a leading provider of integrated ... conference call to discuss its financial results for the ... call is scheduled for 5:00 p.m. ET on Wednesday, ... 643-0580 to access the conference call, or can listen ...
... meal delivery offering to over 30,000 MembersNew Agreement ... Partnership within the new Fitness Industry Sales ChannelFORT ... DIET ), and Diversified Health & Fitness, ... together to promote eDiets, award-winning, fresh-prepared diet meal ...
... Feb. 25 The Quantum Group, Inc. (NYSE Amex: ... Services Organization (HSO), announced today that Senior Vice President ... scheduled to present at the 5th Annual Winter Technology ... is scheduled for 10:30 AM (pacific standard time) on ...
Cached Medicine News:Health News:Mylan's Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor 2Health News:Cherokee Inspired Comfort Awards Program Call for Nominations 2Health News:Cherokee Inspired Comfort Awards Program Call for Nominations 3Health News:American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer 2Health News:American TeleCare, Inc. (ATI) Appoints Michael A. Brodeur as Chief Financial Officer 3Health News:eDiets.com(R) and Diversified Health & Fitness Announce New Strategic Marketing Partnership 2Health News:eDiets.com(R) and Diversified Health & Fitness Announce New Strategic Marketing Partnership 3Health News:eDiets.com(R) and Diversified Health & Fitness Announce New Strategic Marketing Partnership 4Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 2Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 3Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 4
(Date:5/29/2015)... , May 29, 2015 LifeNet Health ... total hiring for 2015 to more than 160 people. ... increased demand for LifeNet Health,s innovative bio-implants, which are ... more patients to be served. It also is a ... industry. "The growth and success of LifeNet ...
(Date:5/29/2015)... Mass. , May 29, 2015  Haemonetics Corporation ... Davies , Chief Operating Officer, will present at the ... York on June 23 rd , 2015 ... may access Mr. Davies, presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
... 49th American Society of ... Hematology Meeting, ... in a pivotal study of patients with indolent,non-Hodgkin,s lymphoma (NHL), whose ... induced a,high rate of response. TREANDA(R) is a novel investigational chemotherapy.,According ...
... HAYWARD, Calif., Dec. 8 Kosan Biosciences,Incorporated ... from a dose-escalating,Phase 1b clinical trial of ... (Velcade(R)), showing durable antitumor,activity and tolerability in ... following treatment with multiple conventional,therapies. The data ...
Cached Medicine Technology:TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 2Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 3Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 4Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 5Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: